News
ALDX
3.930
-0.25%
-0.010
Aldeyra Therapeutics Unveils R&D Progress and Goals
TipRanks · 1d ago
Weekly Report: what happened at ALDX last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at ALDX last week (0408-0412)?
Weekly Report · 04/15 09:44
Weekly Report: what happened at ALDX last week (0401-0405)?
Weekly Report · 04/08 09:46
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
NASDAQ · 04/06 10:37
Aldeyra gains as Perceptive Advisors boosts stake
Perceptive Advisors bought more than $1.9B worth of shares of Aldeyra Therapeutics. The company's lead candidate, reproxalap, is developed with AbbVie. Oppenheimer upgraded the stock to Buy from Hold on Wednesday.
Seeking Alpha · 04/04 14:16
Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Recent notable insider transactions for penny stocks include Aldeyra Therapeutics, Inc. And Retractable Technologies.
Benzinga · 04/04 10:23
Aldeyra's Dry Eye Disease Drug May Be On Path For FDA Approval -- Market Talk
Aldeyra Therapeutics surges 15% to $4.10 after an upgrade from Oppenheimer. Analyst raises Aldeyra to outperform from perform with a $10 price target. Analyst cites company's development plan for resubmitting dry eye disease treatment reproxalap.
Dow Jones · 04/03 18:38
BUZZ-U.S. STOCKS ON THE MOVE-Identiv, Levi Strauss, cannabis firms
Wall Street's main indexes advanced on Wednesday. Softer-than-expected services sector data offered relief to investors. Dow Jones Industrial Average was up 0.14% at 39,226.61. Top three S&P 500 percentage gainers: GE Aerospace, Caesars Entertainment, Ulta Beauty.
Reuters · 04/03 18:01
BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Ulta Beauty, SPAR Group
Spotify, Ulta Beauty, SPAR Group are among the day's top stocks. Wall Street's main indexes swung higher on Wednesday after softer-than-expected services sector data. The Dow Jones Industrial Average was up 0.21% at 39,252.29.
Reuters · 04/03 15:57
Aldeyra Therapeutics Raised to Outperform From Perform by Oppenheimer
Dow Jones · 04/03 14:09
Aldeyra Therapeutics Price Target Announced at $10.00/Share by Oppenheimer
Dow Jones · 04/03 14:09
Oppenheimer Upgrades Aldeyra Therapeutics to Outperform, Announces $10 Price Target
Benzinga · 04/03 13:58
ALDEYRA THERAPEUTICS SHARES RISE 3.9% AFTER OPPENHEIMER UPGRADES TO 'OUTPERFORM'
Reuters · 04/03 13:33
BUZZ-U.S. STOCKS ON THE MOVE-Lenz Therapeutics, Intel, ARCA Biopharma
Strong private payrolls data fanned fears of fewer-than-expected interest rate cuts by the Federal Reserve. Wall Street was set to open lower on Wednesday. Dow e-minis were down 0.08% in early trading. Lenz Therapeutics, Intel, ARCA Biopharma and Dave & Buster's Entertainment were up.
Reuters · 04/03 13:20
Aldeyra gains as Oppenheimer upgrades on revised plans for lead asset
Aldeyra gains as Oppenheimer upgrades on revised plans for lead asset. The biotech's lead candidate, reproxalap, targeted at dry eye disease. Aldeyra to resubmit a marketing application for the drug in H2 2024. AbbVie has signed an option agreement for commercial rights to the drug.
Seeking Alpha · 04/03 13:01
BUZZ-Aldeyra Therapeutics rises after Oppenheimer upgrades to 'outperform'
Aldeyra Therapeutics shares rise 5.6% to $3.75 premarket. Brokerage Oppenheimer upgrades to 'outperform' from 'performer' Company's dry eye disease drug reproxalap to be switched to a different trial design.
Reuters · 04/03 13:00
ALDEYRA THERAPEUTICS <ALDX.O>: OPPENHEIMER RAISES TO OUTPERFORM FROM PERFORM
Reuters · 04/03 12:05
U.S. RESEARCH ROUNDUP-Ally Financial, GE Vernova, Navient
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Ally Financial, GE Vernova, Navient and Navient are among the companies. Analysts cut ratings and target prices on several companies on Wednesday. Some analysts raised their targets for the companies, others cut them.
Reuters · 04/03 07:28
Aldeyra Therapeutics Price Target Announced at $10.00/Share by HC Wainwright & Co.
Dow Jones · 04/02 12:54
More
Webull provides a variety of real-time ALDX stock news. You can receive the latest news about Aldeyra Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.